2018 Shaping the Future of Nanomedicine Symposium

VANCOUVER, July 19, 2018 /CNW/ - Precision NanoSystems announces its third annual Precision NanoSystems Nanomedicines Symposium, entitled Shaping the Future. The Symposium is scheduled for July 21, 2018 in New York City at 3 Club West (off 5th Avenue, steps away from Rockefeller Center). This year's event explores challenges and solutions for the discovery, development and manufacture of molecularly tailored treatments as a part of the vision for medicine's personalized future.

The morning kick-offs with three breakout sessions focusing on the drug development journey: Discovery, Pre-Clinical and Manufacturing. The formal sessions will be led by Frank Slack, Ph.D., Professor Beth Israel Deaconess Medical & Director of the Initiative for RNA Medicine at Harvard Medical School; Yvonne Perrie, Ph.D., Professor Strathclyde University, Glasgow Chair in Drug Delivery, Associate Dean of Research, MHRA Expert Advisor and Dan Peer, Ph.D., Professor Tel Aviv University Laboratory of Precision Nanomedicine.

Our Keynote speakers include Theresa LaVallee, Ph.D., Head of Translational Medicine & Regulatory Affairs of Parker Institute; Martin A. Maier, Ph.D., Vice President of Research at Alnylam Pharmaceuticals and Lawrence Mayer, Ph.D., Senior Vice President of Jazz Pharmaceuticals & Co-Founder of Celator Pharmaceuticals (Retired).

Other highlights of the day will include major announcements from Precision NanoSystems and a reception showcasing scientific posters. For those unable to attend the event in person, you can still enjoy a virtual front row seat via a free livestream. Register now at https://pninanomedlivestream.eventbrite.ca to join the event online.

Date: July 21, 2018 8:30 am to 4:00 pm Eastern Time
What: Third annual Precision Nanosystems Nanomedicines Symposium: "Shaping the Future"
Where: 3 West 51st New York, NY 10019

About Precision NanoSystems, Inc.
Precision NanoSystems Inc. (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI's proprietary NanoAssemblr Platform enables the rapid, reproducible and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com

SOURCE Precision Nanosystems

or follow-up: Precision NanoSystems, Jane Alleva, Global Marketing Manager, Precision NanoSystems, Phone: [phone], ext 140 or mobile [phone], [email protected]